Teriparatide treatment in severe osteoporosis - a controlled 10-year follow-up study.

Kontogeorgos G, Krantz E, Trimpou P, Laine CM, Landin-Wilhelmsen K

BMC musculoskeletal disorders24 Nov 2022Cited by 6 (Europe PMC)

PMID36424580PMCIDPMC9686095DOI10.1186/s12891-022-05987-2PepBankPUB-36424580

Summary

BackgroundTeriparatide was the first anabolic agent recommended for the treatment of osteoporosis. Long-term real-world, controlled studies are not available. The purpose was to evaluate the long-term effects of treatment with teriparatide on fractures and Health Related Quality of Life in subjects with established osteoporosis in comparison with placebo treated patients with osteoporosis and the general population.MethodsA 10-year follow-up was performed after a prospective, open-labelled study with teriparatide 20 μg given subcutaneously daily for a mean of 18 months (range 14-24 months) in 40 women, mean age 69 years, with osteoporosis and vertebral compression. Placebo treated women, n = 25, mean age 60 years, from a randomized, double-blind, placebo-controlled growth hormone trial with daily subcutaneous injections for 18 months, with osteoporosis were used as controls. Dual energy x-ray absorptiometry and questionnaires were performed at start, after 18 months, after 36 months and after 10 years. Women, n = 233, of similar age from a random population sample, also served as controls and were followed in parallel. All fractures were X-ray verified.ResultsFractures decreased from 100 to 35% in the teriparatide treated patients (p < 0.0001) to similar levels as in the population sample, 25 to 28% at start and after 10 years, respectively. Bone mineral density increased on teriparatide but returned to levels at treatment start after 10 years. Health Related Quality of Life was lower in the teriparatide group than in the population (p < 0.001) before and, after treatment and at 10 years.ConclusionsAnabolic hormonal treatment with teriparatide reduced fracture prevalence to similar levels as in the general population at 10 years' follow-up. Health Related Quality of Life was low in osteoporosis and unaffected by bone specific treatment.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study5

4 results from studies that gave the peptide. 4 results from people.

01HumanNon-randomized trialEfficacy outcome
In women with severe osteoporosis, fracture prevalence decreased from 100 to 35% after teriparatide at 10-year follow-up.
In plain wordsIn women with severe osteoporosis, fracture prevalence fell from 100 to 35% after teriparatide at long-term follow-up.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseFracture prevalence at 10 years
Study
n: not reported in source
Comparator
baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg daily · subcutaneous · mean 18 months (range 14-24 months)As given in this study (human).
Measurements
fracture prevalence
100%
baseline
fracture prevalence
35%
teriparatide follow-up
Source sentences
Summary
Fractures decreased from 100 to 35% in the teriparatide treated patients (p < 0.0001) to similar levels as in the population sample, 25 to 28% at start and after 10 years, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
A 10-year follow-up was performed after a prospective, open-labelled study with teriparatide 20 μg given subcutaneously daily for a mean of 18 months (range 14-24 months) in 40 women, mean age 69 years, with osteoporosis and vertebral compression.
Show in the study text Report a problemFND-3642458001
02HumanNon-randomized trialEfficacy outcome
In women with severe osteoporosis, fracture prevalence after teriparatide reached levels similar to the population sample at 10 years.
In plain wordsIn women with severe osteoporosis, fracture prevalence after teriparatide was similar to the population sample at 10 years.
Peptide
Teriparatide (PTH 1-34)
Outcome
Direction not reportedFracture prevalence versus population
Study
n: not reported in source
Comparator
random population sample
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg daily · subcutaneous · mean 18 months (range 14-24 months)As given in this study (human).
Measurements
fracture prevalence
35%
teriparatide group after 10 years
fracture prevalence
25%
population sample at start
fracture prevalence
28%
population sample after 10 years
Source sentences
Summary
Fractures decreased from 100 to 35% in the teriparatide treated patients (p < 0.0001) to similar levels as in the population sample, 25 to 28% at start and after 10 years, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
A 10-year follow-up was performed after a prospective, open-labelled study with teriparatide 20 μg given subcutaneously daily for a mean of 18 months (range 14-24 months) in 40 women, mean age 69 years, with osteoporosis and vertebral compression.
Show in the study text Report a problemFND-3642458002
03HumanNon-randomized trialEfficacy outcome
In women with severe osteoporosis, BMD increased during teriparatide treatment.
In plain wordsIn women with severe osteoporosis, bone density increased during teriparatide treatment compared with treatment start.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseBMD during treatment
Study
n: not reported in source
Comparator
treatment start
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg daily · subcutaneous · mean 18 months (range 14-24 months)As given in this study (human).
Source sentences
Summary
Bone mineral density increased on teriparatide but returned to levels at treatment start after 10 years.
1 context sentence(design, population, supporting numbers)
Summary · context
A 10-year follow-up was performed after a prospective, open-labelled study with teriparatide 20 μg given subcutaneously daily for a mean of 18 months (range 14-24 months) in 40 women, mean age 69 years, with osteoporosis and vertebral compression.
Show in the study text Report a problemFND-3642458003
04HumanNon-randomized trialEfficacy outcome
In women with severe osteoporosis, BMD returned to treatment-start levels 10 years after teriparatide treatment.
In plain wordsIn women with severe osteoporosis, bone density returned to treatment-start levels at 10 years.
Peptide
Teriparatide (PTH 1-34)
Outcome
Direction not reportedBMD at 10 years
Study
n: not reported in source
Comparator
treatment start
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg daily · subcutaneous · mean 18 months (range 14-24 months)As given in this study (human).
Source sentences
Summary
Bone mineral density increased on teriparatide but returned to levels at treatment start after 10 years.
1 context sentence(design, population, supporting numbers)
Summary · context
A 10-year follow-up was performed after a prospective, open-labelled study with teriparatide 20 μg given subcutaneously daily for a mean of 18 months (range 14-24 months) in 40 women, mean age 69 years, with osteoporosis and vertebral compression.
Show in the study text Report a problemFND-3642458004

Studies that did not test the peptide alone1

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

05HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In women with osteoporosis, quality of life was lower in the teriparatide group than the population before, after, and 10 years after treatment.
In plain wordsIn women with osteoporosis, quality of life was lower than the population before and after teriparatide treatment, including at 10 years.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseHealth-related quality of life
Study
n: not reported in source
Comparator
population sample
Outcome group
Quality of life · Whole body
Source sentences
Summary
Health Related Quality of Life was lower in the teriparatide group than in the population (p < 0.001) before and, after treatment and at 10 years.
1 context sentence(design, population, supporting numbers)
Summary · context
A 10-year follow-up was performed after a prospective, open-labelled study with teriparatide 20 μg given subcutaneously daily for a mean of 18 months (range 14-24 months) in 40 women, mean age 69 years, with osteoporosis and vertebral compression.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Show in the study text Report a problemFND-3642458005

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.